HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laura Mercier sale

This article was originally published in The Rose Sheet

Executive Summary

Ada, Michigan-based Alticor has acquired Laura Mercier cosmetics marketer Gurwitch Products from The Neiman Marcus Group, firm announces July 28. Under terms of the agreement, Gurwitch will "operate as a stand-alone, wholly owned subsidiary of Alticor and maintain its current retail distribution channels through high-end department stores and online retailers," firm notes. As part of Alticor, Gurwitch will have "access to additional resources, support and global infrastructure" to help it "bring its business to the next level," while allowing Alticor to "enhance its insight into the luxury cosmetics marketplace," firm adds. Laura Mercier is distributed at Neiman Marcus and Bergdorf Goodman. Gurwitch announced it was exploring strategic options, including sale of the company, in December (1"The Rose Sheet" Dec. 19, 2005, In Brief)...

You may also be interested in...



Gurwitch Products

Laura Mercier marketer Gurwitch Products LLC will explore "various strategic alternatives" including recapitalization or possible sale of the company, firm announces Dec. 9. "We are reviewing many global opportunities to continue to grow our business," Gurwitch Products CEO Janet Gurwitch notes. Investment banking firm Financo, Inc. will assist the 10-year old company, Gurwitch adds...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel